# Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment

> **NCT03768466** · PHASE4 · COMPLETED · sponsor: **Mundipharma Korea Ltd** · enrollment: 123 (actual)

## Conditions studied

- Low Back Pain

## Interventions

- **DRUG:** Brand Name: Targin®

## Key facts

- **NCT ID:** NCT03768466
- **Lead sponsor:** Mundipharma Korea Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-21
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-09-17
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03768466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03768466, "Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Treatment". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03768466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*